JP2012082213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012082213A5 JP2012082213A5 JP2011270382A JP2011270382A JP2012082213A5 JP 2012082213 A5 JP2012082213 A5 JP 2012082213A5 JP 2011270382 A JP2011270382 A JP 2011270382A JP 2011270382 A JP2011270382 A JP 2011270382A JP 2012082213 A5 JP2012082213 A5 JP 2012082213A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- peptide
- composition according
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 102000007079 Peptide Fragments Human genes 0.000 claims 9
- 108010033276 Peptide Fragments Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 108010002687 Survivin Proteins 0.000 claims 8
- 210000000265 leukocyte Anatomy 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 5
- 238000011065 in-situ storage Methods 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 102000043129 MHC class I family Human genes 0.000 claims 3
- 108091054437 MHC class I family Proteins 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 108091007065 BIRCs Proteins 0.000 claims 2
- 238000011510 Elispot assay Methods 0.000 claims 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 2
- 238000010228 ex vivo assay Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000159 protein binding assay Methods 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 1
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/354,090 | 2003-01-30 | ||
| US10/354,090 US20040210035A1 (en) | 2002-01-30 | 2003-01-30 | Survivin-derived peptides and use thereof |
| US10/715,417 | 2003-11-19 | ||
| US10/715,417 US7892559B2 (en) | 2002-01-30 | 2003-11-19 | Survivin-derived peptides and use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005518634A Division JP5121143B2 (ja) | 2003-01-30 | 2004-01-30 | スルビビン誘導ペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012082213A JP2012082213A (ja) | 2012-04-26 |
| JP2012082213A5 true JP2012082213A5 (https=) | 2012-07-12 |
| JP5509185B2 JP5509185B2 (ja) | 2014-06-04 |
Family
ID=46241465
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011270382A Expired - Lifetime JP5509185B2 (ja) | 2003-01-30 | 2011-12-09 | スルビビン誘導ペプチドおよびその使用 |
| JP2012117831A Expired - Lifetime JP5931585B2 (ja) | 2003-01-30 | 2012-05-23 | スルビビン誘導ペプチドおよびその使用 |
| JP2015011806A Expired - Lifetime JP6021961B2 (ja) | 2003-01-30 | 2015-01-23 | スルビビン誘導ペプチドおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012117831A Expired - Lifetime JP5931585B2 (ja) | 2003-01-30 | 2012-05-23 | スルビビン誘導ペプチドおよびその使用 |
| JP2015011806A Expired - Lifetime JP6021961B2 (ja) | 2003-01-30 | 2015-01-23 | スルビビン誘導ペプチドおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2857035B1 (https=) |
| JP (3) | JP5509185B2 (https=) |
| CN (1) | CN103288920B (https=) |
| DK (1) | DK2359841T3 (https=) |
| ES (3) | ES2633389T3 (https=) |
| NO (2) | NO343244B1 (https=) |
| PT (1) | PT2359841E (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604755D0 (en) * | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
| WO2021024742A1 (ja) * | 2019-08-06 | 2021-02-11 | 国立大学法人筑波大学 | 細胞傷害アッセイ方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| ES2225824T3 (es) | 1992-08-31 | 2005-03-16 | Ludwig Institute For Cancer Research | Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos. |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| US6245523B1 (en) * | 1996-11-20 | 2001-06-12 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| EP1066527A2 (en) * | 1998-04-01 | 2001-01-10 | Yale University | Method to identify modulators of survivin - tubulin interaction |
| WO2000003693A1 (en) * | 1998-07-14 | 2000-01-27 | Jenner Biotherapies, Inc. | Survivin, and peptides thereof, as an anti-cancer vaccine |
| DE10225144A1 (de) * | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| WO2005049073A2 (en) * | 2003-11-19 | 2005-06-02 | Survac Aps | Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
-
2004
- 2004-01-30 ES ES14191676.7T patent/ES2633389T3/es not_active Expired - Lifetime
- 2004-01-30 PT PT101808780T patent/PT2359841E/pt unknown
- 2004-01-30 ES ES14191677.5T patent/ES2661082T3/es not_active Expired - Lifetime
- 2004-01-30 DK DK10180878.0T patent/DK2359841T3/en active
- 2004-01-30 EP EP14191677.5A patent/EP2857035B1/en not_active Expired - Lifetime
- 2004-01-30 CN CN201310159752.8A patent/CN103288920B/zh not_active Expired - Lifetime
- 2004-01-30 ES ES10180878.0T patent/ES2529203T3/es not_active Expired - Lifetime
-
2011
- 2011-12-09 JP JP2011270382A patent/JP5509185B2/ja not_active Expired - Lifetime
-
2012
- 2012-05-23 JP JP2012117831A patent/JP5931585B2/ja not_active Expired - Lifetime
-
2015
- 2015-01-23 JP JP2015011806A patent/JP6021961B2/ja not_active Expired - Lifetime
-
2017
- 2017-01-27 NO NO20170133A patent/NO343244B1/no not_active IP Right Cessation
-
2018
- 2018-11-23 NO NO20181511A patent/NO344833B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10722536B1 (en) | Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | |
| ES2860798T3 (es) | Nuevos péptidos y nuevas combinaciones de péptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cáncer | |
| TWI758912B (zh) | 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架 | |
| US10253077B2 (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | |
| ES2832546T3 (es) | Péptidos WT-1 inmunogénicos y métodos de uso de los mismos | |
| JP2020182477A (ja) | 養子細胞療法のための腫瘍浸潤リンパ球 | |
| ES2952959T3 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra diversos tumores (SEQ ID N.º 25 - MXRA5-003) | |
| BR112019015237A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de ovário e outros cânceres | |
| UA124575C2 (uk) | Пептид для лікування раку | |
| BR112019020959A2 (pt) | peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer | |
| EP3273986A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors | |
| AU2017229149A1 (en) | Uterine cancer treatments | |
| CA3072922A1 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| AU2022204032B2 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| CA3223546A1 (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| JP2010521441A5 (https=) | ||
| JP2012082213A5 (https=) | ||
| BR112021010432A2 (pt) | Peptídeo, anticorpo, receptor de célula t, aptâmero, ácido nucleico, célula hospedeira, método in vitro de produção de linfócitos t ativados, llinfócito t, composição farmacêutica, método de produção de um peptídeo e de produção de uma vacina anticâncer, método para matar células alvo em um paciente, utilização e kit | |
| ES2899425T3 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (CHC) y otros tipos de cáncer | |
| TWI755365B (zh) | 用於小細胞肺癌和其他癌症免疫治療的新型肽和肽組合物 | |
| BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
| Liu et al. | Prediction and identification of B cell epitopes derived from EWS/FLI-l fusion protein of Ewing’s sarcoma | |
| TWI772927B (zh) | 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架 | |
| BR112016008254B1 (pt) | Peptídeo que consiste em 4 epítopos de ctl ligados, composição de ctl, e composição farmacêutica |